Last reviewed · How we verify
NCT05254301: UNLOCK
Nutrition and LOComotoric Rehabilitation in Long COVID-19
NA trial testing Intervention group in COVID-19 in 65 participants. Completed in 30 January 2024.
30 January 2024
Quick facts
| Lead sponsor | Universitair Ziekenhuis Brussel |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 65 |
| Start date | 24 April 2022 |
| Primary completion | 30 January 2024 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Intervention group — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Universitair Ziekenhuis Brussel — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Long COVID is a new phenomenon, in which individuals who experienced a SARS-CoV-2 infection still experience one or more symptoms, such as exercise intolerance, fatigue and/or muscle pains in addition to other COVID-related symptoms, weeks to months after initial infection. The aim of this pilot-study is to learn about which complaints patients continue to experience after their infection and how this affects their lives to a greater or lesser extent and whether a patient-tailored physical rehabilitation programme combined with individualised nutritional therapy leads to a faster recovery compared to a classic exercise program with the physiotherapist.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Functional performance recovery after individualized nutrition therapy combined with a patient-tailored physical rehabilitation program versus standard physiotherapy in patients with long COVID: a pilot study.
Roggeman S, Jimenez Garcia BG, Leemans L, Demol J, et al · · 2023 · cited 4× · PMID 37759324 · DOI 10.1186/s40814-023-01392-1 -
Increased physical performance after personalised physiotherapy and nutritional counselling in adults with post-COVID-19 condition: a feasibility randomised trial.
Jimenez Garcia BG, Roggeman S, Leemans L, Cools W, et al · · 2026 · PMID 41775918 · DOI 10.1038/s43856-026-01486-w -
Faster functional performance recovery after individualized nutrition therapy combined with a patient-tailored physical rehabilitation program versus standard physiotherapy in patients with long COVID: a pilot study for a randomized, controlled single-center trial.
Roggeman S, Garcia BJ, Leemans L, Demol J, et al · · 2023 · DOI 10.21203/rs.3.rs-2392494/v1
Verify or expand the search:
- PubMed search for NCT05254301
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intervention group
Trials testing the same drug.
- NCT07379294 — Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery · NA · not yet recruiting
- NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting
- NCT06330480 — Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease · NA · enrolling by invitation
- NCT06879106 — Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation · NA · completed
- NCT06684691 — The Effect of an Escape Room Simulation on Post-mortem Care Training · NA · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Universitair Ziekenhuis Brussel trials
Trials by the same sponsor.
- NCT07536230 — Deep Learning Framework for Continuous Depth of Anesthesia Forecasting · not yet recruiting
- NCT07533968 — The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in I · NA · not yet recruiting
- NCT07289984 — Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders and · NA · not yet recruiting
- NCT06923813 — Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calo · NA · recruiting
- NCT07401004 — Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05254301 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitair Ziekenhuis Brussel
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05254301.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing